Iovance Biotherapeutics stock: Q3 revenue reaches about $122 million

Published on 11/10/2026 at 22:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Iovance Biotherapeutics stock remains tied to commercial execution and lung-cancer development. The company also reported stronger margins in its latest quarter.

Quarterly growth and pipeline focus

Iovance reported stronger commercial momentum and higher gross margin in the third quarter.
Updated lung-cancer data is supporting a more focused development strategy.
Further regulatory and clinical milestones are expected in 2027.

IOVA, US4622601007, Illustration mit AI erstellt.

Iovance Biotherapeutics reported record third-quarter revenue of approximately 122 million US dollars on November 5, according to the company's press release. Total revenue increased approximately 80 percent year over year, while U.S. Amtagvi revenue rose approximately 77 percent. Gross margin reached approximately 60 percent.

Iovance also highlighted updated IOV-LUN-202 results in previously treated non-squamous metastatic non-small-cell lung cancer. The company reported a 24.6 percent objective response rate in 69 patients and a 59.1 percent response rate in a biomarker-selected subgroup. The update supports a precision strategy for lifileucel in lung cancer, with a planned supplemental biologics license application in 2027.

Commercial progress meets development risk

The figures point to improving commercial execution, but the investment case remains dependent on whether Amtagvi demand can support Iovance's broader tumor-infiltrating lymphocyte platform. Clinical progress in lung cancer may expand the opportunity, while enrollment, regulatory review and manufacturing execution remain important milestones.

Iovance Biotherapeutics stock traded at 7.23 euros on Lang & Schwarz at 22:34 CET on Tuesday, November 10, 2026.